Cargando…
Immunogenicity and protective efficacy of SARS-CoV-2 recombinant S-protein vaccine S-268019-b in cynomolgus monkeys
The vaccine S-268019-b is a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S)-protein vaccine consisting of full-length recombinant SARS-CoV-2 S-protein (S-910823) as antigen, mixed with the squalene-based adjuvant A-910823. The current study evaluated the immunogenicity of S-26...
Autores principales: | Hashimoto, Masayuki, Nagata, Noriyo, Homma, Tomoyuki, Maeda, Hiroki, Dohi, Keiji, Seki, Naomi M., Yoshihara, Ken, Iwata-Yoshikawa, Naoko, Shiwa-Sudo, Nozomi, Sakai, Yusuke, Shirakura, Masayuki, Kishida, Noriko, Arita, Tomoko, Suzuki, Yasushi, Watanabe, Shinji, Asanuma, Hideki, Sonoyama, Takuhiro, Suzuki, Tadaki, Omoto, Shinya, Hasegawa, Hideki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Authors. Published by Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9167832/ https://www.ncbi.nlm.nih.gov/pubmed/35691872 http://dx.doi.org/10.1016/j.vaccine.2022.05.081 |
Ejemplares similares
-
Immune response and protective efficacy of the SARS-CoV-2 recombinant spike protein vaccine S-268019-b in mice
por: Homma, Tomoyuki, et al.
Publicado: (2022) -
Homologous and heterologous booster vaccinations of S-268019-b, a recombinant S protein-based vaccine with a squalene-based adjuvant, enhance neutralization breadth against SARS-CoV-2 Omicron subvariants in cynomolgus macaques
por: Hashimoto, Masayuki, et al.
Publicado: (2022) -
Results from a preclinical study in rodents and a Phase 1/2, randomized, double-blind, placebo-controlled, parallel-group study of COVID-19 vaccine S-268019-a in Japanese adults
por: Sonoyama, Takuhiro, et al.
Publicado: (2023) -
Safety and immunogenicity of a booster dose of S-268019-b: Interim findings of a Phase 3, open-label clinical study in Japan
por: Sonoyama, Takuhiro, et al.
Publicado: (2023) -
Immunogenicity and safety of booster dose of S-268019-b or BNT162b2 in Japanese participants: An interim report of phase 2/3, randomized, observer-blinded, noninferiority study
por: Shinkai, Masaharu, et al.
Publicado: (2022)